Traumatic Brain Injury - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 255 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Traumatic Brain Injury - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Traumatic brain injury - Pipeline Review, H1 2016', provides an overview of the Traumatic brain injury pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Traumatic brain injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Traumatic brain injury and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Traumatic brain injury
- The report reviews pipeline therapeutics for Traumatic brain injury by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Traumatic brain injury therapeutics and enlists all their major and minor projects
- The report assesses Traumatic brain injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Traumatic brain injury

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Traumatic brain injury
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Traumatic brain injury pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Traumatic Brain Injury Overview 9
Therapeutics Development 10
Pipeline Products for Traumatic Brain Injury - Overview 10
Pipeline Products for Traumatic Brain Injury - Comparative Analysis 11
Traumatic Brain Injury - Therapeutics under Development by Companies 12
Traumatic Brain Injury - Therapeutics under Investigation by Universities/Institutes 16
Traumatic Brain Injury - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Traumatic Brain Injury - Products under Development by Companies 20
Traumatic Brain Injury - Products under Investigation by Universities/Institutes 24
Traumatic Brain Injury - Companies Involved in Therapeutics Development 25
ALSP, Inc. 25
Amarantus Bioscience Holdings, Inc. 26
Athersys, Inc. 27
BHR Pharma, LLC 28
Cognosci, Inc. 29
Euroscreen S.A. 30
Grupo Ferrer Internacional, S.A. 31
Karyopharm Therapeutics, Inc. 32
Kyorin Pharmaceutical Co., Ltd. 33
Levolta Pharmaceuticals, Inc. 34
Lixte Biotechnology Holdings, Inc. 35
Lpath, Inc. 36
Luc Therapeutics, Inc. 37
MandalMed, Inc. 38
Mapreg S.A.S. 39
Neuralstem, Inc. 40
Neuren Pharmaceuticals Limited 41
NeuroHealing Pharmaceuticals Inc. 42
NeuroNascent, Inc. 43
Neuronax SAS 44
NeuroVive Pharmaceutical AB 45
New World Laboratories, Inc. 46
Novogen Limited 47
Omeros Corporation 48
PharmatrophiX, Inc. 49
Phylogica Limited 50
Premier Biomedical Inc. 51
Prevacus, Inc. 52
QR Pharma, Inc. 53
RegeneRx Biopharmaceuticals, Inc. 54
Remedy Pharmaceuticals, Inc. 55
Sage Therapeutics, Inc. 56
SanBio, Inc. 57
STATegics, Inc. 58
Tetra Discovery Partners LLC 59
vasopharm GmbH 60
VG Life Sciences, Inc. 61
Traumatic Brain Injury - Therapeutics Assessment 62
Assessment by Monotherapy Products 62
Assessment by Combination Products 63
Assessment by Target 64
Assessment by Mechanism of Action 67
Assessment by Route of Administration 70
Assessment by Molecule Type 72
Drug Profiles 74
(levocetirizine dihydrochloride + montelukast sodium) - Drug Profile 74
2-DG - Drug Profile 75
ALP-496 - Drug Profile 77
AMRS-001 - Drug Profile 79
apomorphine hydrochloride - Drug Profile 82
AST-001 - Drug Profile 84
AST-002 - Drug Profile 85
AVL-8168 - Drug Profile 86
Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury - Drug Profile 87
CHEC-7 - Drug Profile 89
CHEC-9 - Drug Profile 90
CNB-001 - Drug Profile 92
coenzyme Q10+ cyanocobalamin + cyclobenzaprine hydrochloride + naltrexone + pyridoxine - Drug Profile 94
COG-1410 - Drug Profile 95
cyclosporine - Drug Profile 97
dexamethasone acetate + melatonin - Drug Profile 100
EPO-Variant - Drug Profile 101
ESN-502 - Drug Profile 102
felbamate - Drug Profile 103
FIB-117 - Drug Profile 104
glyburide - Drug Profile 105
HBI-002 - Drug Profile 108
HBI-137 - Drug Profile 109
HBN-1 - Drug Profile 110
HBN-2 - Drug Profile 111
HPI-201 - Drug Profile 112
HPI-363 - Drug Profile 114
ibudilast - Drug Profile 115
ICCN-100 - Drug Profile 117
JM-4 - Drug Profile 118
KPT-350 - Drug Profile 119
LB-201 - Drug Profile 120
LB-205 - Drug Profile 121
LM11A-31BHS - Drug Profile 122
LM22A-4 - Drug Profile 124
Lpathomab - Drug Profile 125
MAP-4343 - Drug Profile 127
Neu-2000- Drug Profile 128
ND-478 - Drug Profile 130
NNI-370 - Drug Profile 131
NNZ-2591 - Drug Profile 132
NSI-189 - Drug Profile 133
NSI-566 - Drug Profile 135
NVP-019 - Drug Profile 137
NVX-428 - Drug Profile 138
NWL-53 - Drug Profile 139
NX-210 - Drug Profile 140
PF-05285401 - Drug Profile 141
Posiphen - Drug Profile 145
progesterone - Drug Profile 147
PRV-002 - Drug Profile 148
PYC-35 - Drug Profile 149
PYC-36 - Drug Profile 150
PYC-38 - Drug Profile 151
PYC-98 - Drug Profile 152
R-503 - Drug Profile 153
RGN-352 - Drug Profile 155
SB-623 - Drug Profile 157
sepranolone - Drug Profile 159
Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile 162
Small Molecule to Antagonize GPR17 for CNS Disorders - Drug Profile 163
Small Molecules for Stroke and Traumatic Brain Injury - Drug Profile 164
Small Molecules for Traumatic Brain Injury - Drug Profile 165
Small Molecules to Antagonize NMDA2A for Central Nervous System Disorders - Drug Profile 166
Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 167
Small Molecules to Inhibit PBR for Traumatic Brain Injury and Neurodegenerative Diseases - Drug Profile 168
Stem Cell Therapy for Central Nervous System Disorder - Drug Profile 169
Stem Cell Therapy for CNS Disorders - Drug Profile 170
STSE-15 - Drug Profile 171
T-094 - Drug Profile 173
TBI-121 - Drug Profile 174
TBI-122 - Drug Profile 175
TBI-123 - Drug Profile 176
trofinetide - Drug Profile 177
UH-0113 - Drug Profile 180
UH-0213 - Drug Profile 181
VAS-203 - Drug Profile 182
VG-1177 - Drug Profile 184
VitalHeme - Drug Profile 186
VOLT-02 - Drug Profile 187
Traumatic Brain Injury - Recent Pipeline Updates 188
Traumatic Brain Injury - Dormant Projects 237
Traumatic Brain Injury - Discontinued Products 241
Traumatic Brain Injury - Product Development Milestones 242
Featured News & Press Releases 242
Appendix 248
Methodology 248
Coverage 248
Secondary Research 248
Primary Research 248
Expert Panel Validation 248
Contact Us 248
Disclaimer 249

List of Tables
Number of Products under Development for Traumatic Brain Injury, H1 2016 16
Number of Products under Development for Traumatic Brain Injury - Comparative Analysis, H1 2016 17
Number of Products under Development by Companies, H1 2016 18
Number of Products under Development by Companies, H1 2016 (Contd..1) 19
Number of Products under Development by Companies, H1 2016 (Contd..2) 20
Number of Products under Development by Companies, H1 2016 (Contd..3) 21
Number of Products under Investigation by Universities/Institutes, H1 2016 22
Comparative Analysis by Late Stage Development, H1 2016 23
Comparative Analysis by Clinical Stage Development, H1 2016 24
Comparative Analysis by Early Stage Development, H1 2016 25
Products under Development by Companies, H1 2016 26
Products under Development by Companies, H1 2016 (Contd..1) 27
Products under Development by Companies, H1 2016 (Contd..2) 28
Products under Development by Companies, H1 2016 (Contd..3) 29
Products under Investigation by Universities/Institutes, H1 2016 30
Traumatic Brain Injury - Pipeline by ALSP, Inc., H1 2016 31
Traumatic Brain Injury - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016 32
Traumatic Brain Injury - Pipeline by Athersys, Inc., H1 2016 33
Traumatic Brain Injury - Pipeline by BHR Pharma, LLC, H1 2016 34
Traumatic Brain Injury - Pipeline by Cognosci, Inc., H1 2016 35
Traumatic Brain Injury - Pipeline by Euroscreen S.A., H1 2016 36
Traumatic Brain Injury - Pipeline by Grupo Ferrer Internacional, S.A., H1 2016 37
Traumatic Brain Injury - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 38
Traumatic Brain Injury - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016 39
Traumatic Brain Injury - Pipeline by Levolta Pharmaceuticals, Inc., H1 2016 40
Traumatic Brain Injury - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2016 41
Traumatic Brain Injury - Pipeline by Lpath, Inc., H1 2016 42
Traumatic Brain Injury - Pipeline by Luc Therapeutics, Inc., H1 2016 43
Traumatic Brain Injury - Pipeline by MandalMed, Inc., H1 2016 44
Traumatic Brain Injury - Pipeline by Mapreg S.A.S., H1 2016 45
Traumatic Brain Injury - Pipeline by Neuralstem, Inc., H1 2016 46
Traumatic Brain Injury - Pipeline by Neuren Pharmaceuticals Limited, H1 2016 47
Traumatic Brain Injury - Pipeline by NeuroHealing Pharmaceuticals Inc., H1 2016 48
Traumatic Brain Injury - Pipeline by NeuroNascent, Inc., H1 2016 49
Traumatic Brain Injury - Pipeline by Neuronax SAS, H1 2016 50
Traumatic Brain Injury - Pipeline by NeuroVive Pharmaceutical AB, H1 2016 51
Traumatic Brain Injury - Pipeline by New World Laboratories, Inc., H1 2016 52
Traumatic Brain Injury - Pipeline by Novogen Limited, H1 2016 53
Traumatic Brain Injury - Pipeline by Omeros Corporation, H1 2016 54
Traumatic Brain Injury - Pipeline by PharmatrophiX, Inc., H1 2016 55
Traumatic Brain Injury - Pipeline by Phylogica Limited, H1 2016 56
Traumatic Brain Injury - Pipeline by Premier Biomedical Inc., H1 2016 57
Traumatic Brain Injury - Pipeline by Prevacus, Inc., H1 2016 58
Traumatic Brain Injury - Pipeline by QR Pharma, Inc., H1 2016 59
Traumatic Brain Injury - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2016 60
Traumatic Brain Injury - Pipeline by Remedy Pharmaceuticals, Inc., H1 2016 61
Traumatic Brain Injury - Pipeline by Sage Therapeutics, Inc., H1 2016 62
Traumatic Brain Injury - Pipeline by SanBio, Inc., H1 2016 63
Traumatic Brain Injury - Pipeline by STATegics, Inc., H1 2016 64
Traumatic Brain Injury - Pipeline by Tetra Discovery Partners LLC, H1 2016 65
Traumatic Brain Injury - Pipeline by vasopharm GmbH, H1 2016 66
Traumatic Brain Injury - Pipeline by VG Life Sciences, Inc., H1 2016 67
Assessment by Monotherapy Products, H1 2016 68
Assessment by Combination Products, H1 2016 69
Number of Products by Stage and Target, H1 2016 71
Number of Products by Stage and Mechanism of Action, H1 2016 74
Number of Products by Stage and Route of Administration, H1 2016 77
Number of Products by Stage and Molecule Type, H1 2016 79
Traumatic Brain Injury Therapeutics - Recent Pipeline Updates, H1 2016 194
Traumatic Brain Injury - Dormant Projects, H1 2016 243
Traumatic Brain Injury - Dormant Projects (Contd..1), H1 2016 244
Traumatic Brain Injury - Dormant Projects (Contd..2), H1 2016 245
Traumatic Brain Injury - Dormant Projects (Contd..3), H1 2016 246
Traumatic Brain Injury - Discontinued Products, H1 2016 247